Trial Information

Summary: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Status: Completed

Protocol Number: NO16006

Sponsor: Hoffmann-La Roche Inc

Company Division: Pharmaceutical

Official Scientific Title: A randomized, open-label study of the effect of PEGASYS versus Roferon-A on cytogenetic response in patients with chronic myelogenous leukemia

Brief Summary: This study will evaluate the safety and efficacy of PEGASYS compared with Roferon-A in patients with recently diagnosed chronic phase myelogenous leukemia who have not received prior interferon therapy. The anticipated time on study treatment is 12 months or until progressive disease and the target sample size is 500+ individuals. Target sample size is 145.

Study Phase: III

Study Design / Study Details:

  • Purpose: Treatment
  • Allocation: Randomized
  • Masking: Open Label
  • Control: Active
  • Assignment: Parallel
  • Endpoints: Safety/Efficacy

Study Type:

Interventional

Condition: Myelogenous Leukemia, Chronic

Intervention Type: Drug

Intervention Name: peginterferon alfa-2a (40KD)[PEGASYS]

Primary Outcome: 1. Efficacy: Major cytogenetic response based on karyotypic analysis, and complete hematologic response, at 12 months

Key Secondary Outcomes: 1. Safety: Adverse events, laboratory tests results, vital signs, survival rate at 2 years

Inclusion Criteria:

  • adult patients >=18 years of age;
  • confirmed chronic phase myelogenous leukemia diagnosed within 12 months before start of study.

Exclusion Criteria:

  • previous interferon therapy or treatment with any investigational agents;
  • fertile men or women unless surgically sterile or using adequate contraceptive methods, and pregnant or lactating women;
  • candidates for bone marrow transplant within the next 6 months.

Gender: Males or Females

Age Limits: Min: 18 Years

Accepts Healthy Volunteers: No

Trial Registration Date: 07/26/2005

Date Last Updated: 07/15/2008

Link To Trial Results

Contact:

Research Site:
Located In:
Warszawa, Poland, 01-201
Telephone: 973-235-5000 or 800-526-6367

 

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 21, 2008 at 3:18:54 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA